

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants:	Douglas J. ALLEN et al.	)	Confirmation No.: 4376
Serial No.:	10/613,619	)	
Filed:	July 3, 2003	)	Group Art Unit:
		)	1618
For:	2-Methyl-Thieno-Benzodiazepine Formulation	)	Examiner:
		)	Blessing M. Fubara
Docket No.:	X-11666C	)	

**APPLICANTS' INTERVIEW SUMMARY PURSUANT TO 37 C.F.R. § 1.133**  
**(MPEP § 713.04)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a result of a rejection by the Office mailed April 2, 2007, Applicants filed a reply with amendments on June 27, 2007. The Office subsequently conducted a telephonic interview on September 13, 2007 wherein agreement was reached. A Notice of Allowance was mailed October 4, 2007. The substance of that interview is provided below.

**Substance of the Interview Pursuant to MPEP § 713.04**

The telephonic interview was held at the above-cited date between Applicants' representative, Nelsen L. Lentz, and Patent Office Examiner Blessing M. Fubara. Examiner Fubara initiated the interview. No prior art was discussed during this interview. The claims discussed during the interview were pending claims 1, 22, 23, and 34-36.

With regard to claim 1, it was agreed that the word "or" would be replaced with the word "and" between "carrier" and "cholesterol" by examiner's amendment such that claim 1 would read as follows:

1. A formulation comprising olanzapine pamoate monohydrate as an active ingredient and one or more carriers selected from the group consisting of an oleaginous carrier and cholesterol microsphere carrier wherein said formulation has a prolonged sustained release of greater than 7 days and up to 30 days, and a burst release of less than 15% of the active ingredient.

It was agreed that claims 22 and 23 would be canceled by examiner's amendment.

With regard to claims 35 and 36, it was agreed to replace the phrase "the particle size of the olanzapine pamoate monohydrate is" with the phrase "the olanzapine pamoate monohydrate has a particle size of" by examiner's amendment such that claims 35 and 36 would read as follows:

35. A formulation as claimed in claim 34 wherein the olanzapine pamoate monohydrate has a particle size of from about 20 to about 60  $\mu\text{m}$ .

36. A formulation as claimed in claim 34 wherein the olanzapine pamoate monohydrate has a particle size of from about 5 to about 20  $\mu\text{m}$ .

Serial No. 10/613,619

It is respectfully submitted that the above summary of this interview reflects the substance of the interview.

Respectfully submitted,

/Nelsen L. Lentz/

Nelsen L. Lentz  
Attorney for Applicants  
Registration No. 38,537  
Telephone No. (317) 276-1207

Patent Division  
Eli Lilly and Company  
P. O. Box 6288  
Indianapolis, Indiana 46206-6288

October 11, 2007